PepGen (PEPG) Stock Price, News & Analysis

Company Overview

PepGen Inc. is a clinical-stage biotechnology company developing RNA-based therapeutics for severe neuromuscular and genetic diseases. The company’s programs are designed to address conditions caused by genetic mutations by selectively modifying or restoring the production of disease-related proteins.

PepGen’s technology platform, Enhanced Delivery Oligonucleotide (EDO), uses peptide-conjugated phosphorodiamidate morpholino oligomers to improve the delivery of therapeutic oligonucleotides into muscle and other tissues. The platform is intended to support treatments that can alter RNA processing, including exon skipping and other gene-regulating approaches.

The company’s lead program, PGN-EDO51, is being developed for Duchenne muscular dystrophy in patients with mutations amenable to exon 51 skipping. PepGen is also advancing programs for other neuromuscular disorders, including myotonic dystrophy type 1. Founded in 2018 and headquartered in Boston, Massachusetts, PepGen’s research and development activities are focused primarily on rare genetic diseases, with CEO James McArthur among its leadership team.

Key Stats

• Today's Range: $2.39 to $2.65
• 50-Day Range: $1.88 to $3.42
• 52-Week Range: $1.31 to $7.80
• Volume: 603,693 shs
• Average Volume: 806,892 shs
• Market Capitalization: $181.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.40
• Consensus Rating: Moderate Buy

PepGen Stock Analysis - MarketRank™

PepGen scored higher than 35% of companies evaluated by MarketBeat, and ranked 664th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

PepGen has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

PepGen has a consensus price target of $11.40, representing about 335.1% upside from its current price of $2.62.

Amount of Analyst Coverage

PepGen has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for PepGen are expected to decrease in the coming year, from ($1.11) to ($1.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PepGen is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PepGen is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

PepGen has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.18% of the float of PepGen has been sold short.

Short Interest Ratio / Days to Cover

PepGen has a short interest ratio ("days to cover") of 4.77.

Change versus previous month

Short interest in PepGen has recently increased by 9.15%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PepGen does not currently pay a dividend.

Dividend Growth

PepGen does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.55

News Sentiment

PepGen has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for PepGen this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for PEPG on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PepGen insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.30% of the stock of PepGen is held by insiders.

Percentage Held by Institutions

58.01% of the stock of PepGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/11/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PEPG
• CIK: 1835597
• Web: www.pepgen.com
• Phone: 781-797-0979
• Fax: N/A
• Employees: 57
• Year Founded: 2018

Price Target and Rating

• Average Price Target for PepGen: $11.40
• High Price Target: $20.00
• Low Price Target: $4.00
• Potential Upside/Downside: +335.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$89.65 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -51.01%
• Return on Assets: -43.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.36
• Quick Ratio: 13.36

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.14 per share
• Price / Book: 1.22

Miscellaneous

• Outstanding Shares: 69,260,000
• Free Float: 68,360,000
• Market Cap: $181.46 million
• Optionable: Not Optionable
• Beta: 2.01